Trial Profile
PRIME-HCC: Preliminary Assessment of Safety and Bioactivity of the Ipilimumab and Nivolumab Combination Prior to Liver Resection (LR) in Hepatocellular Carcinoma (HCC)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jun 2019
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRIME-HCC
- 07 Jun 2019 Status changed from not yet recruiting to recruiting.
- 27 Sep 2018 New trial record